Shares of ImmuPharma plc (LON:IMM – Get Free Report) rose 23.6% on Friday . The stock traded as high as GBX 4.70 ($0.06) and last traded at GBX 4.33 ($0.05). Approximately 77,650,875 shares traded hands during trading, an increase of 186% from the average daily volume of 27,131,590 shares. The stock had previously closed at GBX 3.50 ($0.04).
ImmuPharma Trading Up 4.9 %
The firm has a market capitalization of £15.30 million, a P/E ratio of -367.30 and a beta of 1.53. The firm has a 50-day moving average of GBX 1.44 and a two-hundred day moving average of GBX 1.65.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Further Reading
- Five stocks we like better than ImmuPharma
- Golden Cross Stocks: Pattern, Examples and Charts
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- How to Calculate Inflation Rate
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
